Drug Quality Under Scrutiny: Are Sudanese Regulations Enough?
"An in-depth look at the perceptions of pharmacists regarding the effectiveness of Sudan's pharmaceutical regulations in ensuring the quality and safety of medicines."
Ensuring the safety, efficacy, and quality of medicines is a cornerstone of public health. Medicines regulation, as defined by the World Health Organization (WHO), is a multifaceted process designed to protect the public by ensuring that all drugs meet the required standards. This includes controlling manufacturing processes, verifying drug quality, assessing efficacy and safety, and ensuring accurate labeling and information.
Across the globe, governments employ various strategies to regulate pharmaceuticals, most commonly requiring registration before a drug can enter the market. Despite these measures, the challenge of substandard and counterfeit drugs persists, especially in developing countries. This article delves into the specifics of pharmaceutical regulation in Sudan, exploring its impact on medicine quality from the perspective of those working directly with drug importation.
This article aims to analyze how pharmacists who own or have shares in Sudanese medicine importing businesses perceive the impact of the government’s Pharmacy, Poisons, Cosmetics and Medical Devices Act on the quality of medicines available in Sudan. It seeks to answer critical questions about the effectiveness of current legislation.
Pharmaceutical Quality Trends
The FDA's Office of Pharmaceutical Quality published the seventh edition of its Report on the State of Pharmaceutical Quality for FY2024. The report provides trend data and analysis on pharmaceutical-production regulation and compliance, including site quality, product quality, site compliance, postmarket reporting, and testing. FDA-conducted drug quality assurance inspections of foreign and domestic manufacturers, including surveillance and for-cause inspections, have increased significantly since the COVID-19 pandemic. These figures describe U.S. regulatory activity and do not by themselves establish the effectiveness of Sudanese regulations.
Risk- and Science-Based Quality
Since the early 2000s, the FDA has advocated a risk- and science-based approach known as quality by design, or QbD, for pharmaceutical quality. ICH guideline Q10 states that a pharmaceutical quality system should routinely achieve the desired product quality, maintain suitable process performance, use appropriate controls, identify improvement opportunities, and continually expand knowledge. ICH also links QbD and quality risk management under Q9 with stronger science- and risk-based regulatory approaches. These methods provide a structured framework, but the cited material does not establish that they are sufficient without effective implementation and oversight.
From Reform to Regulation
The history of pharmaceutical regulation has developed from early drug oversight into a strategic role in global health governance. Legislative reforms played a pivotal role in expanding the pharmaceutical industry by introducing stricter quality and safety controls, regulating drug labeling, and distinguishing prescription medicines from over-the-counter medicines. This historical trajectory shows how regulatory systems were shaped not only by scientific progress but also by legal reforms. The sources do not identify a single founding discovery as the decisive milestone.
Are Current Regulations Enough to Guarantee Drug Quality?
A survey was conducted among 30 pharmacists who are owners or shareholders in medicine importing companies in Sudan. The pharmacists were asked about the effectiveness of existing drug regulations. A significant majority, 89% considered the medicines on the Sudanese market to be of generally good quality. This indicates a positive perception among professionals directly involved in the import and distribution of medicines.
- Splitting of Authority: 91% of respondents believed that dividing drug registration responsibilities between the Ministry of Health (MOH) and the Ministry of Animal Resources (MOAR) weakens overall medicine control. This division potentially creates gaps and inconsistencies in regulatory oversight.
- Non-Registered Medicine Distributors: A significant 93% agreed that the increasing number of non-registered medicine distributors facilitates the marketing of low-quality medicines. This underscores the need for stricter control over the distribution channels to prevent substandard drugs from entering the market.
- Pre-Marketing Surveillance: Nearly three-quarters (71%) felt that pre-marketing surveillance is insufficient to ensure the quality of medicines. This suggests a need for more robust and comprehensive testing and evaluation processes before drugs are released to the public.
Evidence Still Developing
Current discussions of pharmaceutical quality continue to examine how regulatory systems address product safety, efficacy, manufacturing, and distribution. However, no subsection-specific sources were provided for this review. Conclusions about the latest research, including its relevance to Sudan, should therefore be treated cautiously until studies or reviews directly addressing those questions are identified.
Enforcement and Access Gaps
A 2024 narrative review reports that Africa's pharmaceutical sector faces significant challenges, including poor-quality medicines and weak regulatory enforcement. The review argues that addressing these problems is vital to improving health outcomes through the provision of high-quality medicines. Separate reporting on pharmaceutical limitations notes that barriers can arise across research and development, distribution, and patient access, affecting efficacy, safety, affordability, and availability. Together, these sources show why formal standards may fail to protect patients when enforcement and supply-chain conditions are inadequate.
Different Regulatory Frameworks
Comparative regulatory literature examines similarities and differences among systems such as the United States Food and Drug Administration, the European Medicines Agency, and India's Central Drugs Standard Control Organization. Comparisons commonly cover drug approval, manufacturing standards, pharmacovigilance obligations, and the practical requirements for companies operating across markets. Recent work also reports continued demand for global harmonization of science-based standards to streamline drug development and evaluation while improving product quality, safety, and efficacy worldwide. These comparisons can identify possible benchmarks, but the cited material does not rank one system as universally superior.
Strengthening Sudan's Pharmaceutical Future
The study underscores the need for continuous evaluation and improvement of pharmaceutical regulations in Sudan. While the current system has strengths, identified weaknesses must be addressed to safeguard public health effectively.
Quality Requires Lifecycle Oversight
A 2024 analysis of drug and drug-product quality reports that product quality was the leading category among drug-quality issues identified by the FDA's Office of Pharmaceutical Quality from 2016 to 2020. Maintaining quality requires multiple analytical studies of drug substances and products throughout their lifecycle, with heightened attention in recent years to micro- and trace components. Regulatory innovation can also take a holistic approach to the submission, assessment, and lifecycle management of pharmaceutical quality information. The cited expert-consulting source describes experience in FDA regulatory compliance but does not independently establish a specific quality outcome.
Digital and Harmonized Regulation
Forecasts for 2025 and 2026 identify digital submissions, real-world evidence, and global harmonization as important trends in pharmaceutical development. Other outlooks describe accelerated pathways, expanded nonclinical modernization, greater acceptance of digital evidence, and rising expectations for quality, regulatory rigor, and scientific communication. A 2026 standards update also highlights GMP compliance, pharmacopoeia updates, and artificial intelligence in drug development. These are forward-looking industry and regulatory themes rather than confirmed outcomes for Sudan.
Institutions and Implementation
Regulatory bodies use measures such as Good Manufacturing Practices to help ensure the quality of medicines. Broader reviews describe pharmaceutical regulatory organizations as influential in drug development while also facing challenges in ensuring the safety and efficacy of new treatments. This means drug quality depends not only on written rules but also on the capacity of institutions to implement and enforce them. The cited sources provide global context but do not supply a Sudan-specific assessment.
Regulation in Practice
The NIH Drug Regulatory Case Study explains that innovators developing drugs, devices, or biologics need to understand the regulatory processes applicable to their products in order to navigate approval successfully. Research on real-world evidence reports growing momentum for using real-world evidence to inform regulatory decisions in health care. Related regulatory guidance discussions consider real-world data and evidence for drug and biologic decisions, including the use of registries as sources for FDA submissions. These approaches connect regulatory decisions with evidence from health-care practice, although the cited sources do not quantify their impact in Sudan.
Based on the research findings and the pharmacists’ perspectives, the following recommendations can help enhance the pharmaceutical regulatory framework:
<ul> <li><b>Re-evaluate Regulatory Structure:</b> The government should consider consolidating drug regulatory authority under a single entity to avoid inconsistencies and improve coordination.</li> <li><b>Enhance Surveillance and Enforcement:</b> Strengthening pre- and post-marketing surveillance, coupled with stricter control over medicine distribution channels, is essential to prevent the proliferation of low-quality drugs.</li> <li><b>Invest in Resources:</b> Adequate funding and resources should be allocated to drug analysis laboratories and state departments of pharmacy to ensure effective monitoring and enforcement of regulations.</li> <li><b>Address Public Sector Practices:</b> The practice of public sector organizations distributing unregistered medicines should be ceased to maintain the integrity of the regulatory system and prevent unfair competition.</li> </ul>